25 related articles for article (PubMed ID: 38440976)
21. Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma
Mangla B; Mittal P; Kumar P; Javed S; Ahsan W; Aggarwal G
Nanomedicine (Lond); 2024 Apr; 19(10):855-874. PubMed ID: 38440976
[TBL] [Abstract][Full Text] [Related]
22. Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Prescrire Int; 2013 Dec; 22(144):298-303. PubMed ID: 24600734
[TBL] [Abstract][Full Text] [Related]
23. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
24. Intraductal delivery of nanocarriers for ductal carcinoma
Pandey M; Wen PX; Ning GM; Xing GJ; Wei LM; Kumar D; Mayuren J; Candasamy M; Gorain B; Jain N; Gupta G; Dua K
Nanomedicine (Lond); 2022 Oct; 17(24):1871-1889. PubMed ID: 36695306
[TBL] [Abstract][Full Text] [Related]
25. Clinical Trials for Ductal Carcinoma In Situ of the Breast.
Han MS; Khan SA
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):293-301. PubMed ID: 30206737
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
